Dr. Scott E. Delacroix
Claim this profileLSU Healthcare Network / Metairie Multi-Specialty Clinic
Expert in Parotid Gland Cancer
Expert in Prostate Cancer
28 reported clinical trials
63 drugs studied
About Scott E. Delacroix
Education:
- Received MD (Doctor of Medicine) from Louisiana State University School of Medicine, New Orleans, in 1987.
Experience:
- Board Certified in Internal Medicine by the American Board of Internal Medicine.
- Currently practicing at LSU Healthcare Network / Metairie Multi-Specialty Clinic.
Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage I
Stage II
2Prostate Cancer
Global LeaderStage IV
synaptophysin positive
chromogranin positive
Affiliated Hospitals
Clinical Trials Scott E. Delacroix is currently running
Radium-223 + Cabozantinib
for Kidney Cancer with Bone Metastasis
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone.
Recruiting1 award Phase 216 criteria
Standard Therapy + Surgery/Radiation
for Prostate Cancer
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Recruiting2 awards Phase 330 criteria
More about Scott E. Delacroix
Clinical Trial Related5 years of experience running clinical trials · Led 28 trials as a Principal Investigator · 14 Active Clinical TrialsTreatments Scott E. Delacroix has experience with
- Gemcitabine Hydrochloride
- Radiation Therapy
- Bicalutamide
- Flutamide
- Atezolizumab
- Docetaxel
Breakdown of trials Scott E. Delacroix has run
Parotid Gland Cancer
Prostate Cancer
Prostatic Neoplasm
Bladder Cancer
Prostate Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Scott E. Delacroix specialize in?
Is Scott E. Delacroix currently recruiting for clinical trials?
Are there any treatments that Scott E. Delacroix has studied deeply?
What is the best way to schedule an appointment with Scott E. Delacroix?
What is the office address of Scott E. Delacroix?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.